39 results about "Fenfluramine" patented technology

The invention relates to a method for simultaneously detecting seven slimming chemical components which are illegally added to traditional Chinese medicine, health food or cosmetics. According to the method, an appropriate mobile phase and a reasonable elution gradient are adopted during liquid-phase separation, so that the slimming components needing to be detected are effectively separated within 12 min, the analysis time of a sample instrument is shortened by 88%, and the work efficiency is greatly increased. Additionally, the advantages of high separation ability of the HPLC (High Performance Liquid Chromatography) technology, high sensitivity and stronger qualitative ability of the mass spectrum and the like are combined, so screening and confirmation can be simultaneously completed during one operation. By using the method disclosed by the invention, the seven chemical components including sibutramine, fenfluramine, phenolphthalein, ephedrine, caffeine, N,N-bi-demethylation sibutramine and furosemide can be effectively separated, the inspection time can be shortened, and the slimming chemical components which are illegally added to the traditional Chinese medicine, the health food or the cosmetics can be accurately and effectively distinguished.

A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

A method of reducing a particular type of seizure in a human patient diagnosed with Dravet syndrome, by administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a reduction from baseline in seizures of a particular type. The reduction may be of one, two or three specific types of seizures.

The present invention relates to a synergistic composition for the treatment of diabetes in a subject in need thereof, said composition-comprising Trigonelline of concentration ranging between 20 to 30%, amino acids of concentration ranging between 20 to 60%, and soluble fiber of concentration ranging between 10 to 60%, optionally along with pharmaceutically acceptable additives, a process thereof and also, a method of treating diabetes.

Provided herein is a method of treating a selected patient population, wherein the patient population is selected based on a determination that the patients have previously been non-responsive when treated with stiripentol. In some embodiments, the method comprises selecting the patient based on a previously failed treatment with stiripentol, based on lack of efficacy or tolerability. Pharmaceutical compositions and formulations for use in practicing the subject methods are also provided. The method comprises identifying a population of patients diagnosed with Dravet syndrome who were found previously to have been non-responsive when treated with stiripentol. The selected population of patients is then treated by administering, to each identified patient, a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of a day or days, or over a period of weeks, months or years, until the patient exhibits a reduction from baseline in convulsive seizure frequency.

A method of treating and/or preventing symptoms of Doose syndrome in a patient such as a patient previously diagnosed with Doose syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Doose syndrome patients are treated at a preferred dose of less than about 10.0 to about 0.01 mg/kg/day.

A method of reducing dosing of a concomitant medication in a human patient diagnosed with Dravet syndrome, by administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days while reducing the dose of one or more concomitant anti-seizure or anti-epileptic drugs (AEDs) from baseline and thereby decreasing the amount of medication given to the patient while reducing adverse side effects. Pharmaceutical compositions and formulations for use in practicing the subject methods are also provided.

A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT_1D, 5-HT_2A, 5-HT_2C or sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient. RTT patients are treated at a preferred dose of less than about 1.0 mg/kg/day and may be administered as fenfluramine in an amount of between 0.2 to 0.8 mg/kg/day, to a maximum of 30 mg/day in a liquid oral dose.

Described herein is a method of improving seizure control in a patient experiencing uncontrolled seizures persisting 10 minutes or more, comprising administering fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, at a dose of from 0.2 to 1.2 m/kg/day for a period of about 12 hours to about 7 days to a patient having been put into a therapeutic, medically-induced coma via a general anesthetic; and after about 12 hours to about 7 days, weaning the patient from the general anesthetic and assessing whether the seizure control has improved as compared to a pre-treatment time point. The patient experiencing seizures may have epilepsy or epileptic encephalopathy that has led to established status epilepticus (SE), refractory status epilepticus (RSE) or super-refractory status epilepticus (SRSE).

The invention uses super micro shattering and drop pills producing the technology to produce fenfluramine drop pills, reaching the purposes such as increasing speed, and dissolution of disintegration, increasing the medicine stability, reducing the dose of auxiliary materials and decreasing cost, with rapid effect and convenient use. It can be buccal as well as deglutition, has remarkable conformity, and is especially suitable for children, older man, sicker in bed or with difficulty of swallowing.

5-HT receptor agonists are useful in the treatment of a variety of diseases. Provided herein are methods of reducing the incidence and/or severity of seizures in a human patient using a 5-HT receptor agonist, such as, for example, a 5-HT4 agonist (e.g., fenfluramine). Methods of treating epilepsy or epileptic encephalopathy, and/or reducing, ameliorating or eliminating incidence of SUDEP in a subject diagnosed with epilepsy by administering a 5-HT4 agonist (e.g., fenfluramine) to a subject in need thereof are provided. Pharmaceutical compositions for use in practicing the subject methods are also provided.

The invention uses super micro shattering and drop pills producing the technology to produce fenfluramine drop pills, reaching the purposes such as increasing speed, and dissolution of disintegration, increasing the medicine stability, reducing the dose of auxiliary materials and decreasing cost, with rapid effect and convenient use. It can be buccal as well as deglutition, has remarkable conformity, and is especially suitable for children, older man, sicker in bed or with difficulty of swallowing.

The invention uses super micro shattering and propranolol drop pills producing the technology to produce fenfluramine drop pills, reaching the purposes such as increasing speed, and dissolution of disintegration, increasing the medicine stability, reducing the dose of auxiliary materials and decreasing cost, with rapid effect and convenient use. It can be buccal as well as deglutition, has remarkable conformity, and is especially suitable for children, older man, sicker in bed or with difficulty of swallowing.

The present invention relates to the use of buagafuran for the prevention and/or treatment of addiction to amphetamine drugs. The amphetamine-type drugs comprise but are not limited to amphetamine, methamphetamine, fenfluramine, phentermine, amphetamine sulfate, methylene dioxymetham-phetamine, Tenamfetamine, dimethyl phenylethylamine or one or more of pharmaceutically acceptable salts of the above-mentioned substances.

The invention discloses a rapid detection method for illegally adding illicit drug fenfluramine in health food. The method comprises the following steps of: (1) taking a to-be-detected sample, addingwater and a reagent A, shaking, and centrifuging or standing; and (2) taking the supernatant liquid after centrifugation or standing, adding a reagent B and a reagent C, shaking, continuously adding areagent D and a reagent E, shaking, standing, and observing the color of the upper layer solution after standing and layering. The reagent A is one or more of hydrochloric acid solution, sulfuric acid solution, and glacial acetic acid. The reagent B is aqueous solution of p-nitroaniline. The reagent C is one or two of sodium nitrite solution and potassium nitrite solution. The reagent D is one ormore of sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate. The reagent E is one or more of n-butyl alcohol, chloroform, diethyl ether and, petroleum ether. The detection method is more environmentally friendly, rapid and accurate, obvious in color development, high in sensitivity, simple and convenient to operate, free of any large instruments, and wide in adaptability range.

The invention discloses a method for simultaneously detecting sibutramine and fenfluramine in weight-losing health care products, and belongs to the field of food detection. According to the method disclosed by the invention, the Raman characteristic peaks of sibutramine and fenfluramine which exist at the same time are determined; then pretreating a weight-losing health care product sample, and extracting by adopting an extraction solvent to obtain a solution to be detected; and judging whether sibutramine and fenfluramine exist in the to-be-detected sample or not according to the Raman spectrum of the to-be-detected solution. According to the method disclosed by the invention, the lowest detection concentration of sibutramine and fenfluramine in the weight-losing health-care product is 25mg/kg, qualitative analysis can be carried out on existence of sibutramine and fenfluramine in the weight-losing health-care product, and the detection time of a single sample is controlled within 2min.